GlassScriptPhysician profile
Brian W Russ
NPI 1437169737
$12,164.27
in general payments reported to CMS, 2019-2025
31 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $335 · 2021: $1,195 · 2022: $2,209 · 2023: $2,599 · 2024: $2,580 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,103 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,103.13 |
| Education | $322.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,002.47 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,387.35 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $864.71 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $835.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $769.15 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $748.57 | 2019-2025 | |
| Genzyme Corporation | $688.84 | 2019-2025 | |
| Ucb, INC. | $671.68 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $603.93 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $488.02 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $420.38 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $234.63 | 2021-2024 | |
| Leo Pharma INC. | $175.93 | 2021-2025 | Anzupgo, Adbry |
| Dermira, INC. | $148.26 | 2019-2021 | |
| Dermavant Sciences, INC. | $130.57 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $118.27 | 2021-2025 | Nemluvio |
| Journey Medical Corporation | $110.66 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $107.44 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.23 | 2023-2024 | Cyltezo |
| Prugen, INC. Pharmaceuticals | $91.03 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.45 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $72.08 | 2022 | |
| Epi Health, LLC | $70.67 | 2021-2022 | |
| Almirall LLC | $64.16 | 2021-2024 | Klisyri |
| Vyne Pharmaceuticals INC. | $47.23 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $46.19 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $23.25 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.98 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $17.59 | 2020 | |
| Nabriva Therapeutics, Plc | $16.00 | 2022 | |
| Celgene Corporation | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Russ listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.